Diadema Partners LP Vertex Pharmaceuticals Inc Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Diadema Partners LP holds 57,400 shares of VRTX stock, worth $27.6 Million. This represents 9.92% of its overall portfolio holdings.
Number of Shares
57,400Holding current value
$27.6 Million% of portfolio
9.92%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding VRTX
# of Institutions
1,752Shares Held
227MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$13.6 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11.2 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.2 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.75 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$5.01 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $123B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...